# Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

> **NCT02302833** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Locally Advanced Paraganglioma
- Metastatic Adrenal Gland Pheochromocytoma
- Metastatic Paraganglioma
- Regional Adrenal Gland Pheochromocytoma
- Unresectable Adrenal Gland Pheochromocytoma
- Unresectable Paraganglioma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02302833
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-17
- **Primary completion:** 2024-11-12
- **Final completion:** 2024-11-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02302833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02302833, "Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02302833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*